[TABLE OF CONTENTS]

1 INTRODUCTION OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY: POINT-OF-CARE DIAGNOSTICS MARKET

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS

4 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE

5 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 GLUCOSE TESTING
5.2.1 HB1AC TESTING
5.2.2 COAGULATION TESTING
5.3 FERTILITY/PREGNANCY
5.4 INFECTIOUS DISEASE
5.4.1 HIV POC
5.4.2 CLOSTRIDIUM DIFFICILE POC
5.4.3 HBV POC
5.4.4 PNEUMONIA OR STREPTOCOCCUS ASSOCIATED INFECTIONS
5.4.5 RESPIRATORY SYNCYTIAL VIRUS (RSV) POC
5.4.6 HPV POC
5.4.7 INFLUENZA/FLU POC
5.4.8 HCV POC
5.4.9 MRSA POC
5.4.10 TB
5.4.11 DRUG-RESISTANT TB POC
5.4.12 HSV POC
5.4.13 COVID-19
5.4.14 OTHER 
5.5 CARDIAC MARKERS
5.6 THYROID STIMULATING HORMONE
5.7 HAEMATOLOGY
5.8 PRIMARY CARE SYSTEMS
5.9 DECENTRALIZED CLINICAL CHEMISTRY
5.10 FAECES
5.11 LIPID TESTING
5.12 CANCER MARKER
5.13 BLOOD GAS/ELECTROLYTES
5.14 AMBULATORY CHEMISTRY
5.15 DRUG OF ABUSE (DOA) TESTING
5.16 URINALYSIS/NEPHROLOGY

6 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY END USERS
6.1 OVERVIEW
6.2 CLINICS
6.3 HOSPITALS
6.4 HOMECARE
6.5 ASSISTED LIVING HEALTHCARE FACILITIES
6.6 LABORATORY 

7 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM
7.1 OVERVIEW
7.2 LATERAL FLOW ASSAY
7.3 DIPSTICKS
7.4 MICROFLUIDICS
7.5 MOLECULAR DIAGNOSTICS
7.6 IMMUNOASSAYS

8 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY GEOGRAPHY
8.1 OVERVIEW

8.2 NORTH AMERICA

8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO

8.3 EUROPE

8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE

8.4 ASIA PACIFIC

8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC

8.5 MIDDLE EAST & AFRICA

8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA

8.6 SOUTH AMERICA

8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA

9 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES

10 COMPANY PROFILES

10.1 ABBOTT LABORATORIES
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.2 ROCHE DIAGNOSTICS
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.3 SIEMENS HEALTHINEERS AG
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.4 DANAHER CORPORATION
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.5 BECTON, DICKINSON AND COMPANY
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.6 QUIDEL CORPORATION
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.7 BIOMÉRIEUX SA
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.8 SYSMEX CORPORATION
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.9 NOVA BIOMEDICAL CORPORATION
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.10 TRINITY BIOTECH PLC
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.11 HOLOGIC, INC.
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.12 SEKISUI DIAGNOSTICS, LLC
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.13 EKF DIAGNOSTICS HOLDINGS PLC
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.14 PTS DIAGNOSTICS
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.15 CHEMBIO DIAGNOSTIC SYSTEMS INC
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.16 ORASURE TECHNOLOGIES INC
10.16.1 OVERVIEW
10.16.2 FINANCIAL PERFORMANCE
10.16.3 PRODUCT OUTLOOK
10.16.4 KEY DEVELOPMENTS
10.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.17 BIO-RAD LABORATORIES INC
10.17.1 OVERVIEW
10.17.2 FINANCIAL PERFORMANCE
10.17.3 PRODUCT OUTLOOK
10.17.4 KEY DEVELOPMENTS
10.17.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.18 LUMIRADX
10.18.1 OVERVIEW
10.18.2 FINANCIAL PERFORMANCE
10.18.3 PRODUCT OUTLOOK
10.18.4 KEY DEVELOPMENTS
10.18.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.19 MAGNASENSE TECHNOLOGIES
10.19.1 OVERVIEW
10.19.2 FINANCIAL PERFORMANCE
10.19.3 PRODUCT OUTLOOK
10.19.4 KEY DEVELOPMENTS
10.19.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.20 SPECTRAL MEDICAL INC
10.20.1 OVERVIEW
10.20.2 FINANCIAL PERFORMANCE
10.20.3 PRODUCT OUTLOOK
10.20.4 KEY DEVELOPMENTS
10.20.5 KEY STRATEGIC MOVES AND DEVELOPMENTS